Wednesday, July 8, 2026

Drug profile · INN

inamrinone lactate

inamrinone lactate (INOCOR) is a phosphodiesterase 3a inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — inamrinone lactate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

inamrinone lactate (INOCOR) is a phosphodiesterase 3a inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN inamrinone lactate
Brand INOCOR
Mechanism Phosphodiesterase 3A inhibitor
Target cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Phosphodiesterase 3A inhibitor

Primary target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. cilostazol Phosphodiesterase 3A inhibitor
  2. dyphylline Phosphodiesterase 4 inhibitor
  3. milrinone lactate Phosphodiesterase 3A inhibitor

Frequently asked questions

What is inamrinone lactate?

inamrinone lactate (INOCOR) is a phosphodiesterase 3a inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for inamrinone lactate?

INOCOR is a marketed brand name for inamrinone lactate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of inamrinone lactate?

inamrinone lactate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.